National Jewish Health, 1400 Jackson Street, Denver, Colorado 80206, USA.
Nat Rev Drug Discov. 2010 Feb;9(2):129-40. doi: 10.1038/nrd2958. Epub 2010 Jan 22.
Idiopathic pulmonary fibrosis (IPF) is the most common and most lethal diffuse fibrosing lung disease, with a mortality rate that exceeds that of many cancers. Recently, there have been many clinical trials of novel therapies for IPF. The results have mostly been disappointing, although two treatment approaches have shown some efficacy. This Review describes the difficulties of treating IPF and the approaches that have been tried or are in development, and concludes with suggestions of future therapeutic targets and strategies.
特发性肺纤维化（IPF）是最常见和最致命的弥漫性肺纤维化疾病，其死亡率超过许多癌症。最近，有许多针对 IPF 的新型治疗方法的临床试验。尽管两种治疗方法显示出一定的疗效，但结果大多令人失望。这篇综述描述了治疗 IPF 的困难以及已经尝试或正在开发的方法，并对未来的治疗靶点和策略提出了建议。
